← Leaderboards
Sharon Riddler
University Of Pittsburgh At Pittsburgh
$22,034,939
Attributed
$48,439,646
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,439,646 · 11
By mechanism
UM1$29,777,623 · 1
U01$18,610,217 · 3
M01$51,806 · 7
Top collaborators
- John W Mellors20 shared
- Susan L Koletar15 shared
- Bernard Jonas C Macatangay9 shared
- Urvi M. Parikh1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Amy L Hartman$17,863,276
- Susan L Koletar$31,986,005
- John W Mellors$70,850,753
- Lawrence P Kane$11,819,892
- Louis D Falo$30,012,458
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsParticipantHiv VaccineVirologyFollow-UpClinical ResearchAcquired Immunodeficiency SyndromeLaboratoriesDisease RemissionSafetyResponseViralEvaluationRandomizedProtocols DocumentationResidual StateCellsPlacebosPlasmaIn VivoImmunologicsClinical Trials UnitDouble-Blind MethodOhio
Grant awards (43)
Pitt-Ohio State Clinical Trials Unit$2,382,302
UM1 · FY2025 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$1,083,959
UM1 · FY2025 · AI · contact PI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$948,892
U01 · FY2025 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$119,250
UM1 · FY2025 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$2,310,879
UM1 · FY2024 · AI · contact PI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$1,070,482
U01 · FY2024 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$2,468,833
UM1 · FY2023 · AI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$2,087,709
U01 · FY2023 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$2,355,644
UM1 · FY2022 · AI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$1,695,141
U01 · FY2022 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit$2,344,903
UM1 · FY2021 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure$1,184,950
U01 · FY2021 · AI · contact PI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$1,011,413
U01 · FY2021 · AI · contact PI
PItt-Ohio State-Georgetown Clinical Trials Unit$2,751,253
UM1 · FY2020 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure$1,879,702
U01 · FY2020 · AI · contact PI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure$1,173,561
U01 · FY2020 · AI · contact PI
Pitt-Ohio State Clinical Trials Unit Administrative Supplement$533,144
UM1 · FY2020 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit$3,366,355
UM1 · FY2019 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure$1,387,573
U01 · FY2019 · AI · contact PI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure$1,871,420
U01 · FY2018 · AI · contact PI
PItt-Ohio State-Georgetown Clinical Trials Unit$1,528,540
UM1 · FY2018 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit$1,491,683
UM1 · FY2017 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure$1,065,423
U01 · FY2017 · AI · contact PI
Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation$652,643
U01 · FY2017 · AI · contact PI
PItt-Ohio State-Georgetown Clinical Trials Unit$1,491,683
UM1 · FY2016 · AI
Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation$1,111,436
U01 · FY2016 · AI · contact PI
PItt-Ohio State-Georgetown Clinical Trials Unit$1,446,339
UM1 · FY2015 · AI
Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation$829,507
U01 · FY2015 · AI · contact PI
PItt-Ohio State-Georgetown Clinical Trials Unit$4,102,856
UM1 · FY2014 · AI
Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation$640,365
U01 · FY2014 · AI · contact PI
RAND PHI EVAL IMMUNIZ W/HIGHLY CONSERVED HIV-1 DER PEPT INFLU MATRIX$23,413
M01 · FY2005 · RR
AN ASSESSMENT OF ORAL MUCOSAL IMMUNITY IN HIV-1 INFECTION - VERSION 10$9,818
M01 · FY2005 · RR
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/$1,441
M01 · FY2005 · RR
ACTG A5079: A PROSPECTIVE, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF$719
M01 · FY2005 · RR
IMMUNIZ. W/HIGHLY CONSERVED HIV-1 DER. INFLU. MATRIX$5,342
M01 · FY2004 · RR
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/$2,748
M01 · FY2004 · RR
A Prospective Analysis of Body Composition in Men Enrolled in the Multicenter$2,747
M01 · FY2004 · RR
ASSESSMENT OF ORAL MUCOSAL IMMUNITY IN HIV-1 INFECTION$2,544
M01 · FY2004 · RR
T 20 W/ ABACAVIR AMPRENAVIR, RITONAVIR, EFAVIRENZ IN HIV$0
M01 · FY2002 · RR
T 20 W/ ABACAVIR AMPRENAVIR, RITONAVIR, EFAVIRENZ IN HIV$0
M01 · FY2002 · RR
T 20 W/ ABACAVIR AMPRENAVIR, RITONAVIR, EFAVIRENZ IN HIV$0
M01 · FY2001 · RR
MULTICENTER 34 WEEK STUDY OF INVINAVIR/NELFINAVIR IN HIV 1 SEROPOSITIVE PATIENTS$3,034
M01 · FY2000 · RR
T 20 W/ ABACAVIR AMPRENAVIR, RITONAVIR, EFAVIRENZ IN HIV$0
M01 · FY2000 · RR